OLIVIA LEBER: Open Payments
NPI 1396486551 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,245 in 82 payments from 14 companies in 2025. Trend: 2023 $960 · 2024 $710 · 2025 $1,245
Food & beverage: $1,245
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 14 | $192 |
| ABBVIE INC. | 12 | $163 |
| Janssen Pharmaceuticals, Inc | 12 | $156 |
| Vanda Pharmaceuticals Inc. | 11 | $154 |
| Otsuka America Pharmaceutical, Inc. | 12 | $152 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Tris Pharma Inc | 3 | $63 |
| Alkermes, Inc. | 3 | $61 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
Products named: REXULTI, VRAYLAR, SPRAVATO, FANAPT, Auvelity, CAPLYTA, Sunosi, TRINTELLIX.
Industry payments across MS — which companies pay providers there.
